Companies › Shanghai JMT-Bio
11 active drug programs in 19 registered trials: 8 Phase 1, 7 Phase 3, 4 Phase 2; Oncology, Other, Metabolic and endocrine; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Kn-026 (KN026) Receptor protein-tyrosine kinase erbB-2 inhibitor | ERBB2 | Phase 3 | Early or Locally Advanced HER2-positive Breast Cancer; First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer; Resectable HER2-positive Breast Cancer; Stomach Cancer … | Nov 2026 |
| JMT101 Anti-EGFR monoclonal antibody | EGFR | Phase 3 | Locally Advanced or Metastatic Non-squamous NSCLC; Local Advanced or Metastatic NSCLC | Nov 2026 |
| Osimertinib mesylate Epidermal growth factor receptor erbB1 inhibitor | EGFR | Phase 3 | Non-Small Cell Lung Cancer; Local Advanced or Metastatic NSCLC | Nov 2026 |
| Glumetinib MEK inhibitor | MAP2K1 | Phase 3 | Non-Small Cell Lung Cancer | Feb 2028 |
| JSKN003 HER2-targeted antibody-drug conjugate | – | Phase 3 | Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants | Dec 2028 |
| JMT108 unclear mechanism | – | Phase 1 | Unresectable Locally Advanced or Metastatic Melanoma; Advanced Malignant Tumors | Nov 2026 |
| JMT206 GLP-1 receptor agonist | – | Phase 1 | Healthy Participants; Valid MeSH Conditiongs | Feb 2027 |
| JMT203 Injection anti-GFRAL monoclonal antibody | GFRAL | Phase 1 | Non Small Cell Lung Cancer | Aug 2027 |
| JMT106 Injection | – | Phase 1 | Advanced Solid Tumor | Nov 2028 |
| JMT202 injection | – | Phase 1 | Hypertriglyceridemia | – |
| JMT601 anti-CD20 monoclonal antibody | MS4A1 | Phase 1 | B-cell Non Hodgkin Lymphoma | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06725524 | JMT601 | Phase 1 | B-cell Non Hodgkin Lymphoma | Oncology | Dec 2025 |
| NCT07140809 | JMT202 injection | Phase 1 | Hypertriglyceridemia | Metabolic and endocrine | Jul 2026 |
| NCT07419698 | JMT206 | Phase 1 | Healthy Participants | Other | Sep 2026 |
| NCT05427383 | Kn-026 (KN026) | Phase 2 | Stomach Cancer | Oncology | Nov 2026 |
| NCT06391944 | JMT101 | Phase 2 | Local Advanced or Metastatic NSCLC | Oncology | Nov 2026 |
| NCT06391944 | Osimertinib mesylate | Phase 2 | Local Advanced or Metastatic NSCLC | Oncology | Nov 2026 |
| NCT07280832 | JMT108 | Phase 1 | Unresectable Locally Advanced or Metastatic Melanoma | Oncology | Nov 2026 |
| NCT06747338 | Kn-026 (KN026) | Phase 3 | Early or Locally Advanced HER2-positive Breast Cancer | Oncology | Dec 2026 |
| NCT06023758 | Kn-026 (KN026) | Phase 2 | HER2-positive Locally Advanced Resectable Gastric Cancer | Oncology | Dec 2026 |
| NCT07840729 | JMT206 | Phase 1 | Valid MeSH Conditiongs | Other | Feb 2027 |
| NCT06868849 | JMT203 Injection | Phase 1 | Non Small Cell Lung Cancer | Oncology | Aug 2027 |
| NCT05838066 | Kn-026 (KN026) | Phase 3 | First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer | Oncology | Dec 2027 |
| NCT06829459 | Glumetinib | Phase 3 | Non-Small Cell Lung Cancer | Oncology | Feb 2028 |
| NCT06829459 | Osimertinib mesylate | Phase 3 | Non-Small Cell Lung Cancer | Oncology | Feb 2028 |
| NCT06877650 | JMT108 | Phase 1 | Advanced Malignant Tumors | Oncology | Mar 2028 |
| NCT07275073 | JMT106 Injection | Phase 1 | Advanced Solid Tumor | Oncology | Nov 2028 |
| NCT06846437 | JSKN003 | Phase 3 | Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants | Oncology | Dec 2028 |
| NCT06735391 | JMT101 | Phase 3 | Locally Advanced or Metastatic Non-squamous NSCLC | Oncology | May 2029 |
| NCT07441460 | Kn-026 (KN026) | Phase 3 | Resectable HER2-positive Breast Cancer | Oncology | Aug 2034 |
Pierre Fabre Medicament DualityBio Jiangsu Alphamab Biopharmaceuticals R-Pharm BioRay Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.